Moderna CEO Stéphane Bancel received an annual compensation package worth $19.87 million last year, the largest he’s ever ...

CompanyOverview|NASDAQ:MRNA] The CEO of Moderna Inc. (NASDAQ: MRNA) just purchased $5 million of stock in the open market.

Five years after the start of the pandemic, the fight over who owns the underlying technologies that made the Covid-19 ...

Citi initiated coverage of Moderna (MRNA) with a Neutral rating and $40 price target Healthcare policy remains a key biopharma sector ...

Patent Trial and Appeal Board (PTAB) docket entries indicate that the PTAB has invalidated all challenged claims of Moderna’s ...

Moderna Inc., a biotechnology and pharmaceutical company reorienting its business for a post-pandemic age, awarded almost $17 ...

Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U ...

Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic ...

The door may now be open for additional challenges to patents covering mRNA vaccine technologies, paving the way for increased competition in the ...

Barclays 27th Annual Global Healthcare Conference March 11, 2025 1:30 PM ETCompany ParticipantsRose Loughlin - EVP of ...

Despite high R&D spending and cash burn, Moderna aims for breakeven by 2028, driven by new vaccine opportunities. Explore ...

Moderna (NASDAQ:MRNA) shares jumped 16% on Wednesday, March 5, following a favorable German court decision that determined ...